A Phase 2 interventional study of Avastin and Erbitux in Barrett's Esophagus Without Dysplasia, Barrett Oesophagitis With Dysplasia and Esophageal Adenocarcinoma, sponsored by University Medical Center Groningen. Recruiting at 1 site in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-13.
Sponsored by University Medical Center Groningen · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies in Adenocarcinoma Of Esophagus with a site in Netherlands — 11 open to participants now, 16 under way, 3 of them phase 3. Adenocarcinoma Of Esophagus · Netherlands.
Among the 25 studies in Adenocarcinoma Of Esophagus with a site in Netherlands, this one is the 14th largest by planned enrollment of the 17 interventional ones that give a count, is one of 5 that started in 2023, is one of 7 in phase 2, reaches primary completion later than 4 of the 15 other live ones, and was the 16th registered.
353 studies on the registry are indexed under Adenocarcinoma Of Esophagus; 80 are open to participants now.
Browse Adenocarcinoma Of Esophagus studies →11 of the 25 studies in Adenocarcinoma Of Esophagus with a site in Netherlands are open now. Recruiting first, the newest first:
AstraZeneca · Sites in Netherlands, United States, Australia and 21 more countries
Ages 18+
Erasmus Medical Center · Sites in Netherlands
Ages 18+
UMC Utrecht · Sites in Netherlands
Ages 18+
Amsterdam UMC, location VUmc · Sites in Netherlands
Ages 18+
Daiichi Sankyo · Sites in Netherlands, United States, Argentina and 15 more countries
Ages 18+
A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →
Of the 70 Adenocarcinoma Of Esophagus studies recruiting now, 60 (86%) set no upper age limit and 2 (3%) stop at 75 or younger; 4 take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 9 · Phase 3 4
First in 2002; this study’s year is marked. 5 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 25 is below the median of 51 across 276 interventional studies indexed under Adenocarcinoma Of Esophagus.
Median enrollment 195 across the 17 interventional studies, 308 across the 8 observational. Of the 6 that completed or were terminated, 1 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 25 have an industry lead sponsor. The 10 most frequent:
University Medical Center Groningen is the lead sponsor of 627 studies on the registry; 175 are open to participants now.
University Medical Center Groningen has 2 studies filed under Adenocarcinoma Of Esophagus — fewer than ten, so there is no comparison to draw.
4 of the studies in Adenocarcinoma Of Esophagus with a site in Netherlands that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05188313Phase 3Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)TRAstuzumab and Pertuzumab for HER2+ Resectable Oesophageal Cancer | 2027-07 |
| NCT06687876Amsterdam UMC, location VUmcMetformin as a Metabolic Intervention in Oesophageal Adenocarcinomas to Improve Response to Neoadjuvant Chemoradiotherapy | 2026-12 |
| NCT05642338Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)A Multicenter Prospective Cohort Study Comparing Random Biopsies Versus Wide-Area Transepithelial Brush-Sampling (WATS) for Surveillance of Barrett's Esophagus, the WATS-EURO2 Study | 2027-05-01 |
| NCT04295811Lucid Diagnostics, Inc.Efficacy of EsoGuard Assay on Esophageal Surface Cells Collected With EsoCheck vs EGD for the Diagnosis of BE or EAC | 2027-06-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 25 studies in Adenocarcinoma Of Esophagus with a site in Netherlands, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Previous studies have confirmed the great potential of quantitative fluorescence molecular endoscopy (qFME) when looking at additional lesion detection initially missed by high-definition white light endoscopy (HD-WLE) for surveillance of Barrett's esophagus.
However, the investigators hypothesized, that additional lesions can potentially be identified by simultaneous use of two targeted tracers because of variable expression of vascular endothelial growth factor A (VEGFA) and epidermal growth factor receptor (EGFR )within oesophageal adenocarcinoma (EAC). Until now, solely intravenous and topical administration of the tracers has been investigated. However, optimization of tracer administration and shortened incubation is necessary for clinical translation and implementation of this new technique from Barrett's esophagus (BE) expert centers to regional non-expert centers. BE surveillance procedures normally takes up to 15 minutes at regional hospitals, of which most of the procedural time is needed to take biopsies according to the Seattle protocol. Introducing qFME into these hospitals would elongate the procedure time with at least 10 - 15 minutes. This would increase healthcare costs and put increased pressure on BE healthcare. Ideally, the gastroenterologist can immediately start with the qFME procedure without any incubation time while maintaining the best target-to-background ratios (TBR) possible. Oral administration by drinking the tracer prior to the procedure would eliminate incubation time and its consequences. Quantified qFME with oral tracer administration and targeted biopsies could potentially replace the time-consuming, high miss rate Seattle protocol, improve lesion detection and decrease global healthcare costs associated with BE.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dose finding of oral bevacizumab-800CW and extend optimal dose group (n = 5 - 10)
Drug: Avastin · Device: Fluorescence endoscopy and multi-diameter single fiber reflectance/single fiber fluorescence (MDSFR/SFF) spectroscopy
Dose finding of oral cetuximab-800CW in first five patients and combined oral bevacizumab-800CW and cetuximab-800CW if the investigators see good results with cetuximab-800CW. If not, they will add a control group of non-dysplastic BE patients and administer oral bevacizumab-800CW. (n = 15)
Drug: Avastin · Drug: Erbitux · Device: Fluorescence endoscopy and multi-diameter single fiber reflectance/single fiber fluorescence (MDSFR/SFF) spectroscopy
This arm will only be part of the study when oral administration is not feasible or safe. Compare single topical tracer administration of bevacizumab-800CW with combined topical tracer administration of bevacizumab-800CW and cetuximab-800CW. Extend combined group when lesion detection is increased or add control group with non-dysplastic BE patients if not. (n = 20)
Drug: Avastin · Drug: Erbitux · Device: Fluorescence endoscopy and multi-diameter single fiber reflectance/single fiber fluorescence (MDSFR/SFF) spectroscopy
Orally administered
Also known as: Bevacizumab
Orally administered
Also known as: Cetuximab
Fluorescent endoscope fiber and spectroscopy probe will be inserted through the working channel of the normal clinical therapeutic endoscope
Feasibility of shortening qFME procedural time by oral administration of bevacizumab-800CW and cetuximab-800CW for the detection of BE neoplasia.
Evaluating the performance of qFME with oral administration of bevacizumab-800CW and cetuximab-800CW for detection of neoplasia in BE patients compared to HD-WLE. This comparison will be based on target-to-background rations calculated from the in vivo fluorescence images and quantified by MDSFR/SFF spectroscopy measurements
Time frame: 12 months
Evaluate if the combination of tracers improves lesion detection by the number of invisible lesions detected
Increased lesion detection in % compared to previously gathered amount of invisible lesions with topical tracer administration
Time frame: 12 months
Collect safety data on oral administration of (combined) bevacizumab-800CW and cetuximab-800CW.
Blood pressure in millimeters of mercury (mmHg)
Time frame: Five minutes before and ten minutes after tracer administration
Heart rate
Beats per minute
Time frame: Five minutes before and ten minutes after tracer administration
Temperature
Degrees Celsius
Time frame: Five minutes before and ten minutes after tracer administration
To (semi)quantify and evaluate the in vivo fluorescent signal of bevacizumab-800CW and cetuximab-800CW
Correlate and validate fluorescence signals detected in vivo with ex vivo histopathology grade of dysplasia and VEGFA and EGFR expression
Time frame: 12 months
Eventually further specify and objectify the improvement of qFME by standardisation
Determining optimal pre-set features for gain and exposure times for our fluorescence camera system
Time frame: 12 months
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2023 (actual). Primary completion is estimated for May 2026, 32 months after the start.
Of 51 non-industry phase 2 interventional studies under Adenocarcinoma Of Esophagus, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 82. This study's planned 32 months is below that.
Counting every sponsor, half of 60 studies reached it within 55 months; a quarter within 41 and three quarters within 80.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bevacizumab
University Medical Center Groningen →